Post by iSTAR Medical

𝐅𝐢𝐯𝐞-𝐘𝐞𝐚𝐫 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐫𝐨𝐦 𝐒𝐓𝐀𝐑-𝐆𝐋𝐎𝐁𝐀𝐋 𝐓𝐫𝐢𝐚𝐥 𝐑𝐞𝐢𝐧𝐟𝐨𝐫𝐜𝐞 𝐌𝐈𝐍𝐈𝐣𝐞𝐜𝐭® 𝐚𝐬 𝐚 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐯𝐞 𝐆𝐥𝐚𝐮𝐜𝐨𝐦𝐚 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 We are proud to share new 𝐟𝐢𝐯𝐞-𝐲𝐞𝐚𝐫 𝐝𝐚𝐭𝐚 from our STAR-GLOBAL trial, demonstrating the sustained efficacy and safety of MINIject®, the only commercially available supraciliary MIGS implant. Key outcomes include: ✅ 38% sustained reduction in IOP ✅ 83% of patients with >20% IOP reduction ✅ Favorable safety profile maintained at 5 years, including corneal health Over 5,000 patients have now benefited from MINIject® since its initial rollout – a milestone that reflects growing trust in this minimally invasive, long-term solution for open-angle glaucoma. We invite you to read the full press release for a comprehensive overview of the results and our next steps in development and commercialization as an independent company. #MIGS #Patientoutcomes #MINIject